Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia

NCT01332487 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01332487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01332487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
August 31, 2010
Completion date
August 31, 2010
Enrollment
4,068 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic hyperplasia